Lexicon Pharmaceuticals Shares Owned By Institutions vs. Price To Sales

LXRX Stock  USD 0.69  0.02  2.82%   
Based on Lexicon Pharmaceuticals' profitability indicators, Lexicon Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Lexicon Pharmaceuticals' ability to earn profits and add value for shareholders. At this time, Lexicon Pharmaceuticals' Days Sales Outstanding is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 326.90 in 2024, whereas Price To Sales Ratio is likely to drop 208.67 in 2024. At this time, Lexicon Pharmaceuticals' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 405.4 K in 2024, despite the fact that Operating Income is likely to grow to (163.2 M).
For Lexicon Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lexicon Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lexicon Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lexicon Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lexicon Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.71)
Revenue Per Share
0.018
Quarterly Revenue Growth
9.802
Return On Assets
(0.44)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lexicon Pharmaceuticals Price To Sales vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lexicon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lexicon Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Lexicon Pharmaceuticals is rated fourth overall in shares owned by institutions category among its peers. It is rated below average in price to sales category among its peers fabricating about  0.58  of Price To Sales per Shares Owned By Institutions. The ratio of Shares Owned By Institutions to Price To Sales for Lexicon Pharmaceuticals is roughly  1.73 . At this time, Lexicon Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexicon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Lexicon Price To Sales vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Lexicon Pharmaceuticals

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
82.02 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Lexicon Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
47.37 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Lexicon Price To Sales Comparison

Lexicon Pharmaceuticals is currently under evaluation in price to sales category among its peers.

Lexicon Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lexicon Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lexicon Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Lexicon Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Lexicon Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income31 K32.5 K
Operating Income-171.8 M-163.2 M
Net Loss-177.1 M-168.3 M
Income Tax Expense386.1 K405.4 K
Income Before Tax-177.1 M-168.3 M
Total Other Income Expense Net-5.4 M-5.6 M
Net Loss-157.9 M-165.7 M
Non Operating Income Net Other1.8 M1.9 M
Net Loss-117.2 M-123.1 M
Interest Income6.2 M6.5 M
Net Interest Income-2.6 M-2.7 M
Change To Netincome10.4 M8.8 M
Net Loss(0.80)(0.84)
Income Quality 0.91  0.96 
Net Income Per E B T 0.91  0.54 

Lexicon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lexicon Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lexicon Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lexicon Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Lexicon Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
All  Next Launch Module

Use Investing Themes to Complement your Lexicon Pharmaceuticals position

In addition to having Lexicon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Growth Funds Thematic Idea Now

Small Growth Funds
Small Growth Funds Theme
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.